Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease

Atherosclerosis

Volumn 145, Issue 1, 1999, Pages 51-60

  Fiotti, Nicola ^a   Giansante, Carlo ^a   Ponte, Euro ^a   Delbello, Claudia ^a   Calabrese, Salvatore ^a   Zacchi, Tiberio ^b   Dobrina, Aldo ^a   Guarnieri, Gianfranco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Acute phase reactants; Interleukin 1; Interleukin 6; Soluble cytokine receptors; Tumor necrosis factor

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CYTOKINE; HAPTOGLOBIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKOCYTE ELASTASE; OROSOMUCOID; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE PHASE RESPONSE; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTERY DISEASE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HUMAN; INFLAMMATION; INTERMITTENT CLAUDICATION; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; LIMB ISCHEMIA; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREADMILL EXERCISE;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; ANTIGENS, CD11; ARTERIOSCLEROSIS; CYTOKINES; EXERCISE TEST; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-6; LEUKOCYTE COUNT; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET ACTIVATING FACTOR; RECEPTORS, CYTOKINE; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032971934     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00013-1     Document Type: Article

References (48)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for 1990s. Nature. 362:1993;801-809.
2. Munro J.M., Cotran R.S. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab. Invest. 58:1988;249-261.
3. Alexander R.W. Inflammation and coronary artery disease. N. Engl. J. Med. 331:1994;468-469.
4. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
5. Wallsh E., Weinstein G.S., Franzone A., Clavel A., Rossi P.A., Kreps E. Inflammation of the coronary arteries in patients with unstable angina. Tex. Heart. Inst. J. 13:1986;105-108.
6. Fuster V. Human lesion studies. Ann. NY Acad. Sci. 811:1997;207-224.
7. Rus H.G., Vlaicu R., Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 127:1996;263-271.
8. Steel D.M., Whitehead A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today. 15:1994;81-88.
9. Gewurz H., Zhang X.H., Lint T.F. Structure and function of the pentraxins. Curr. Opin. Immunol. 7:1995;54-64.
10. Vejar M., Fragasso G., Hackett D., Lipkin D.P., Maseri A., Born G.V., Ciabattoni G., Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb. Haemost. 63:1990;163-168.
11. Ciabattoni G., Ujang S., Sritara P., Andreotti F., Davies G., Simonetti B.M., Patrono C., Maseri A. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. J. Am. Coll. Cardiol. 21:1993;1377-1381.
12. Carry M., Korley V., Willerson J.T., Weigelt L., Ford-Hutchinson A.W., Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia: in vivo evidence for 5 lipoxygenase activation. Circulation. 85:1992;230-236.
13. Latini R., Bianchi M., Correale E., Dinarello C.A., Fantuzzi G., Fresco C., Maggioni A.P., Mengozzi M., Romano S., Shapiro L., Sironi M., Tognoni G., Turato R., Ghezzi P. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interlekin-1 receptor antagonist. J. Cardiovasc. Pharmacol. 23:1994;1-6.
14. Maury C.P.J., Teppo A.M. Circulating tumor necrosis factor-α (cachectin) in myocardial infarction. J. Intern. Med. 225:1989;333-336.
15. Neumann F.J., Ott I., Gawaz M., Richardt G., Holzapfel H., Jochum M., Schömig A. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 92:1995;748-755.
16. Hasday D., Scheinowitz M., Leibovitz E., Sclarovsky S., Eldar M., Barak V. Increased serum concentrations of interleukin-1β in patients with coronary artery disease. Heart. 76:1996;24-28.
17. Berk B.C., Weintraub W.S., Alexander R.W. Evaluation of C-reactive protein in 'active' coronary artery disease. Am. J. Cardiol. 65:1990;168-172.
18. Liuzzo G., Biasucci L.M., Gallimore J.R., Grillo R.L., Rebuzzi A.G., Pepys M.B., Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331:1994;417-424.
19. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, for ECAT and DAPSG. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-466.
20. 1-antitrypsin in acute myocardial infarction. Br. Heart. J. 49:1983;26-29.
21. Cimminiello C., Arpaia G., Toschi V., Rossi F., Aloisio M., Motta A., Bonfardeci G. Plasma levels of tumor necrosis factor and endothelial response in patients with chronic arterial obstructive disease or Raynaud phenomenon. Angiology. 45:1994;1015-1022.
22. Fernandez-Botran R., Chilton P.M., Ma Y. Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Adv. Immunol. 63:1996;269-336.
23. Dinarello C.A. Biological basis for Interleukin-1 in disease. Blood. 87:1996;2095-2147.
24. Tilg H., Vannier E., Vachino G., Dinarello C.A., Mier J.M. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL) receptor antagonist over IL-1β synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178:1993;1629-1636.
25. European working group on critical limb ischemia. Second European consensus document on chronic critical leg ischemia. Circulation Supplement 1991;84:IV1-IV26.
26. Carlos T.M., Harlan J.M. Membrane proteins involved in phagocyte adherence to endothelium. Immunol. Rev. 114:1990;5-28.
27. Bellavite P., Dri P., Della Bianca V., Serra M.C. The measurement of superoxide anion production by granulocytes in whole blood. A clinical test for the evaluation of phagocyte function and serum opsonic capacity. Eur. J. Clin. Invest. 13:1983;363-368.
28. Glantz S.A. Primer of Biostatistics. 4th edition:1997;496 McGraw-Hill, New York.
29. Norušis MJ. SPSS/PC+Advanced Statistics 4.0. Chicago IL. SPSS, 1990:B1-B37.
30. Blann A.D., Seigneur M., Adams R.A., McCollum C.N. Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous oxygen in peripheral atherosclerosis. Eur. J. Vasc. Endovasc. Surg. 12:1996;218-222.
31. Gougerot-Podicalo M.A., Elbim C., Chollet-Mertin S. Modulation of the oxidative burst of human neutrophils by pro- and anti-inflammatory cytokines. Pathol. Biol. Paris. 44:1996;36-41.
32. Kitagawa S., Yuo A., Yagisawa M., Azuma E., Yoshida M., Furukawa Y., Takahashi M., Masuyama J., Takaku F. Activation of human monocyte functions by tumor necrosis factor: rapid priming for enhanced release of superoxide and erythrophagocytosis, but no direct triggering of superoxide release. Exp. Hematol. 24:1996;559-567.
33. Bemelmans M.H., van Tits L.J., Buurman W.A. Tumor necrosis factor: function, release and clearance. Crit. Rev. Immunol. 16:1996;1-11.
34. Martich G.D., Danner R.L., Ceska M., Suffredini A.F. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J. Exp. Med. 173:1991;1021-1024.
35. Kusuhara H., Matsuyuki H., Okumoto T. Effects of nonsteroidal anti-inflammatory drugs in Interleukin-1 receptor antagonist production in cultured human peripheral blood mononuclear cells. Prostaglandins. 54:1997;795-804.
36. Gabay C., Smith M.F., Eidlen D., Arend W.P. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J. Clin. Invest. 99:1997;2930-2940.
37. Ganapathi M.K., Schultz D., Mackiewicz A., Samols D., Hu S.I., Brabenec A., Macintyre S.S., Kushner I. Heterogeneous nature of the acute phase response. Differential regulation of human serum amyloid A, C-reactive protein, and other acute phase proteins by cytokines in Hep 3B cells. J. Immunol. 141:1988;564-569.
38. Steel D.M., Whitehead A.S. Heterogeneous modulation of acute phase reactant mRNA levels by interleukin-1 beta and interleukin-6 in the human hepatoma cell line PLC/PFR/5. Biochem. J. 277:1991;477-482.
39. Christman J.W., Holden E.P., Blackwell T.S. Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit. Care Med. 23:1995;955-963.
40. Preas H.L. II, Reda D., Tropea M., Vandivier R.W., Banks S.M., Agosti J.M., Suffredini A.F. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood. 88:1996;2465-2472.
41. Galve-de Rochemonteix B., Wiktorowicz K., Kushner I., Dayer J.M. C-reactive protein increases production of IL-1α, IL-1β and TNF-α, and expression of mRNA in human alveolar macrophages. J. Leuk. Biol. 53:1993;439-445.
42. Xia D., Lin C., Yun J., Wagner T., Magnuson T., Samols D. Transgenic mice expressing rabbit C-reactive protein (CRP) resists endotoxinemia. FASEB J. 5:1991;1628.
43. Heuertz T.Z., Piquette C.A., Webster R.O. Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am. J. Pathol. 142:1993;319-328.
44. Heinrich J., Schulte H., Schonfeld R., Kohler E., Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb. Haemost. 73:1995;374-379.
45. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336:1997;973-979.
46. Su S.J., Yeh T.M. Effects of alpha 1-acid glycoprotein on tissue factor expression and tumor necrosis factor secretion in human monocytes. Immunopharmacology. 34:1996;139-145.
47. Raj A., Gao X., Ray B.K. Role of distal enhancer containing a functional NF-kappa B-binding site in lipopolysaccharide-induced expression of a novel alpha 1-antitrypsin gene. J. Biol. Chem. 270:1995;29201-29208.
48. Chao J., Chen L.M., Chai K.X., Chao L. Expression of kallikrein-binding protein and alpha 1-antitrypsin genes in response to sex hormones, growth, inflammation and hypertension. Agents Actions Suppl. 38:1992;174-181.